Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.
JAMA 2024; 331: 1714-1721.
Some 3020 women with non-metastatic breast cancer were enrolled. The study was terminated after the first interim analysis for futility. 300mg aspirin per day for a median of 33.8 months did not improve breast cancer recurrence (hazard ratio 1.27, 95 per cent confidence interval 0.99 to 1.63, P=0.06) or survival (1.19, 0.82 to 1.72).
Comment: Theoretical advantage not proven.
16 August 2024
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
